Sagent Pharmaceuticals

Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

Company Growth (employees)
Schaumburg, US
Size (employees)
440 (est)
Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, US

Sagent Pharmaceuticals Office Locations

Sagent Pharmaceuticals has an office in Schaumburg
Schaumburg, US (HQ)
1901 N. Roselle Road

Sagent Pharmaceuticals Data and Metrics

Sagent Pharmaceuticals Financial Metrics

Sagent Pharmaceuticals's revenue was reported to be $318.3 m in FY, 2015 which is a 10% increase from the previous period.

Revenue (FY, 2015)

318.3 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

87.7 m

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

(21.9 m)

EBIT (FY, 2015)

(47.1 m)

Market capitalization (29-Aug-2016)

716.1 m

Closing share price (29-Aug-2016)


Cash (31-Dec-2015)

29 m
Sagent Pharmaceuticals's current market capitalization is $716.1 m.
USDFY, 2013FY, 2014FY, 2015


244.8 m289 m318.3 m

Revenue growth, %


Cost of goods sold

167.2 m202.8 m230.6 m

Gross profit

77.5 m86.2 m87.7 m

Gross profit Margin, %


Operating expense total

54.1 m67.1 m84.7 m


29 m15.1 m(47.1 m)

EBIT margin, %


Interest expense

(930 k)(2.2 m)(770 k)

Pre tax profit

30.5 m16.2 m(48.1 m)

Income tax expense

895 k(23.7 m)(26.2 m)

Net Income

29.6 m39.9 m(21.9 m)
USDFY, 2013FY, 2014FY, 2015


42.3 m55.6 m29 m


6.5 m5.6 m7.4 m

Current Assets

235.8 m198.5 m191.6 m


57.7 m71.2 m19.8 m


6 m28.2 m25.2 m

Total Assets

310.2 m381.5 m349.7 m

Accounts Payable

24.9 m32.7 m43.7 m

Total Debt

8 m

Current Liabilities

63.5 m85.6 m83.7 m

Additional Paid-in Capital

349.3 m353 m367.2 m

Retained Earnings

(114.1 m)(74.2 m)(99 m)

Total Equity

236 m275.8 m251.1 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.3 x1.4 x1.4 x
USDFY, 2013FY, 2014FY, 2015

Net Income

29.6 m39.9 m(21.9 m)

Depreciation and Amortization

7.1 m9.5 m13.7 m

Accounts Receivable

8.6 m(16 m)(9.3 m)


(3.5 m)2.2 m(2.6 m)

Cash From Operating Activities

49.6 m23.2 m(7.5 m)

Capital Expenditures

(1.1 m)(4.2 m)(6.7 m)

Cash From Investing Activities

(97.2 m)(932 k)(22 m)

Long-term Borrowings

(9 m)(10.4 m)(471 k)

Cash From Financing Activities

62.3 m(8.5 m)3.5 m

Interest Paid

652 k1.4 m414 k

Income Taxes Paid

2.6 m4.3 m

Free Cash Flow

50.7 m27.4 m(812 k)
USDY, 2015


2.5 m

Financial Leverage

1.4 x

Sagent Pharmaceuticals News and Updates

Sagent Pharmaceuticals Company Life and Culture

You may also be interested in